MXPA05011243A - Benzopiranos substituidos como agonistas selectivos del receptor beta de estrogeno. - Google Patents

Benzopiranos substituidos como agonistas selectivos del receptor beta de estrogeno.

Info

Publication number
MXPA05011243A
MXPA05011243A MXPA05011243A MXPA05011243A MXPA05011243A MX PA05011243 A MXPA05011243 A MX PA05011243A MX PA05011243 A MXPA05011243 A MX PA05011243A MX PA05011243 A MXPA05011243 A MX PA05011243A MX PA05011243 A MXPA05011243 A MX PA05011243A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
selective estrogen
beta agonists
substituted benzopyrans
benzopyrans
Prior art date
Application number
MXPA05011243A
Other languages
English (en)
Inventor
Timothy Ivo Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA05011243A publication Critical patent/MXPA05011243A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Esta invencion se refiere a heterociclos novedosos que son antagonistas en el receptor de hormona de concentracion de melanina 1 (MCHR1), tambien denominados como 11CBy, a composiciones farmaceuticas que los contienen, a procedimientos para su preparacion, y a su uso en medicinas. Los compuestos de la invencion tienen la formula (I).
MXPA05011243A 2003-04-21 2004-04-08 Benzopiranos substituidos como agonistas selectivos del receptor beta de estrogeno. MXPA05011243A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46440403P 2003-04-21 2003-04-21
PCT/US2004/009272 WO2004094400A2 (en) 2003-04-21 2004-04-08 Substituted benzopyrans as selective estrogen receptor-beta agonists

Publications (1)

Publication Number Publication Date
MXPA05011243A true MXPA05011243A (es) 2005-12-15

Family

ID=33310882

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011243A MXPA05011243A (es) 2003-04-21 2004-04-08 Benzopiranos substituidos como agonistas selectivos del receptor beta de estrogeno.

Country Status (17)

Country Link
US (3) US7442812B2 (es)
EP (1) EP1626974B1 (es)
JP (1) JP4481300B2 (es)
CN (1) CN100374444C (es)
AT (1) ATE406373T1 (es)
AU (1) AU2004232798B2 (es)
BR (1) BRPI0409588A (es)
CA (1) CA2518819A1 (es)
CY (1) CY1110443T1 (es)
DE (1) DE602004016150D1 (es)
DK (1) DK1626974T3 (es)
ES (1) ES2311838T3 (es)
MX (1) MXPA05011243A (es)
PL (1) PL1626974T3 (es)
PT (1) PT1626974E (es)
SI (1) SI1626974T1 (es)
WO (1) WO2004094400A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023085A (zh) 2004-07-19 2007-08-22 詹森药业有限公司 用作雌激素受体调节剂的螺－苯并[c]色烯衍生物
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
US7354951B2 (en) 2004-10-18 2008-04-08 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
EP1853578A1 (en) 2005-02-15 2007-11-14 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
JP2006232727A (ja) * 2005-02-24 2006-09-07 Chisso Corp クマリン誘導体、この化合物を含有する液晶組成物およびこの液晶組成物を含有する液晶表示素子
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
EP2647376A1 (en) 2007-01-22 2013-10-09 Gtx, Inc. Nuclear receptor binding agents
WO2011014516A1 (en) 2009-07-28 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Estrogen antagonists as treatments for sclerosing disorders
CN109134493A (zh) * 2018-09-19 2019-01-04 浙江师范大学 一种具有抗菌活性的2-氧代色烯并噻吩衍生物及其合成方法和应用
CN109400564B (zh) * 2018-09-25 2021-03-12 信阳师范学院 一种含三氟甲基的苯并二氢吡喃-4-酮类化合物及其制备方法
CN110128393B (zh) * 2019-06-21 2022-09-30 华侨大学 一种取代异香豆素衍生物的制备方法
CN112898263B (zh) * 2021-01-28 2022-03-08 江西中医药大学 一种从佛手中分离的香豆素骈木脂素化合物及其保肝用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100263137B1 (ko) 1995-09-08 2000-08-01 오테스코그 페르 오판 수용체
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
US6593322B1 (en) * 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2000055137A1 (en) * 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
CN1358091A (zh) * 1999-04-16 2002-07-10 阿斯特拉曾尼卡有限公司 雌激素受体－β配体
DE60018215T2 (de) 1999-12-30 2006-02-09 Signal Pharmaceuticals Llc, San Diego Verbindungen und verfahren zur modulation von estrogen rezeptoren
US7214706B2 (en) * 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
EP1272471B1 (en) 2000-03-27 2007-10-03 N.V. Organon Non-steroidal, tetracyclic compounds for estrogen-related treatments
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
US7147876B2 (en) 2001-08-13 2006-12-12 Michael Hargreaves Riley Compositions for removal of toxins
EA007382B1 (ru) * 2001-11-19 2006-10-27 Эли Лилли Энд Компани Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6914074B2 (en) 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists
ATE457308T1 (de) * 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
US7354951B2 (en) * 2004-10-18 2008-04-08 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
EP1853578A1 (en) 2005-02-15 2007-11-14 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists

Also Published As

Publication number Publication date
BRPI0409588A (pt) 2006-04-18
ES2311838T3 (es) 2009-02-16
PL1626974T3 (pl) 2009-01-30
US20090298925A1 (en) 2009-12-03
DE602004016150D1 (de) 2008-10-09
DK1626974T3 (da) 2008-11-17
ATE406373T1 (de) 2008-09-15
AU2004232798A1 (en) 2004-11-04
CN100374444C (zh) 2008-03-12
CY1110443T1 (el) 2015-04-29
US7842822B2 (en) 2010-11-30
US20070106082A1 (en) 2007-05-10
CN1777614A (zh) 2006-05-24
PT1626974E (pt) 2008-11-14
EP1626974A2 (en) 2006-02-22
WO2004094400A2 (en) 2004-11-04
US7585985B2 (en) 2009-09-08
US20080312312A1 (en) 2008-12-18
US7442812B2 (en) 2008-10-28
SI1626974T1 (sl) 2009-02-28
AU2004232798B2 (en) 2010-04-22
WO2004094400A3 (en) 2005-02-24
JP2006524240A (ja) 2006-10-26
EP1626974B1 (en) 2008-08-27
CA2518819A1 (en) 2004-11-04
JP4481300B2 (ja) 2010-06-16

Similar Documents

Publication Publication Date Title
TW200510429A (en) Heterocyclic MCHR1 antagonists
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
UA83659C2 (ru) Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
WO2003028641A3 (en) Mch receptor antagonists
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
AU2003246811A8 (en) Terphenyl derivatives, preparation thereof, compositions containing same
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
EP2338886A3 (en) Naphthalene derivatives
IL180603A (en) 3,4-Dihydro-1 H- Naphthalanones which are glucocorticoid receptor modulators
MXPA05011243A (es) Benzopiranos substituidos como agonistas selectivos del receptor beta de estrogeno.
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
HK1068349A1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
AU1285801A (en) 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists
HK1091200A1 (en) Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists
ATE457308T1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
WO2001029066A3 (en) Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them
MX2007003307A (es) 4-bencil-1,3-dihidro-imidazol-2-tionas substituidas y no substituidas que actuan como agonistas adrenergicos alfa2 especificos o selectivos y metodos de uso de las mismas.
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors

Legal Events

Date Code Title Description
FG Grant or registration